ORM-1023

**ORM-1023** is an investigational degrader-antibody conjugate developed by Orum Therapeutics for **small cell lung cancer** and **neuroendocrine tumors**. It uses Orum's TPD² platform to selectively deliver a proprietary GSPT1-targeting protein-degrader payload to cancer cells through an antibody directed at an undisclosed cell-surface antigen. The intended mechanism is intracellular degradation of GSPT1, a translation-termination factor implicated in cancer-cell survival, while antibody-mediated targeting is intended to improve tumor selectivity relative to systemically distributed small-molecule degraders. Publicly reported information places ORM-1023 at the discovery or pre-candidate stage, with no clinical trial, formulation, dose, route, or manufacturing details disclosed.

Other names

anti-PD-1-Cbl-bi conjugateanti-PD1-Cbl-bi conjugateanti-PD 1-Cbl-bi conjugatePD-1-Cbl-bi TPS²anti-PD-1/CBL-Bi ADC